

The 7th International Advanced Course on Vaccinology

IVI, Seoul, May 7-12, 2007

AGENDA

DAY 1: Monday, May 7, 2006

900 930 Welcome address and IVI introduction J Clemens/L Jodar

EPIDEMIOLOGY

Chairperson: J Clemens

930 1030 Observational methods in vaccine evaluation C Tam TAB 1
 1030 1045 Coffee break
 1045 1215 Periods and measures of transmissibility J Kuritsky TAB 2
 1215 1330 Lunch
 1330 1400 Advanced concepts in vaccine evaluation B Letson TAB 3
 1400 1430 Molecular typing of pathogen: principles and methods JS Chun TAB 4
 1430 1500 Ethical principles and review P Kilgore TAB 5
 1500 1515 Coffee break

IMMUNOBIOLOGY

Chairperson: L Jodar

1515 1600 Vaccine concepts: immunological basis C Czerkinsky TAB 6
 1600 1645 Assessment of immune responses in humans N Mielcarek TAB 7
 1800 2000 **Welcome reception** at the IVI Lobby

DAY 2: Tuesday, May 8, 2006

MOVING FROM DISCOVERY TO LICENSED PRODUCT (I)

Chairperson: C Tam

830 900 Antigen delivery systems (adjuvants, DNA-based vaccines, recombinant viral vaccines) M Denis TAB 8
 900 930 Immunological basis of mucosal vaccines M Kweon TAB 9
 930 1000 Case study:
 can adjuvants play a role in the development of a pandemic H5N1 candidate vaccine M Denis TAB 10
 1000 1015 Coffee break
 1015 1100 Development and GMP production of vaccines: shigella ribosomal vaccines R Carbis TAB 11
 1100 1130 Managing intellectual property in vaccine development R Mahoney TAB 12
 1130 1230 Lunch

Chairperson: R Mahoney

1230 1400 New vaccine evaluation: phase I - III J Clemens TAB 13
 1400 1415 Coffee break
 1415 1500 Evaluating new vaccines in a landscape of existing vaccines M Knoll TAB 14
 1500 1530 Risk and benefit consideration in vaccine development and licensing S Shin TAB 15
 1600 **Seoul sightseeing**

DAY 3: Wednesday, May 9, 2006

MOVING FROM LICENSING TO INTRODUCTION

Chairperson: L Chocarro

900	940	Phase 3B studies: demonstration projects	J Clemens	TAB 21
940	1020	Post-marketing surveillance (Phase 4 studies)	H Margolis	TAB 22
1020	1035	Coffee break		
1035	1115	Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a re-analysis	J Clemens	TAB 23
1115	1200	IVI laboratory tour	R Carbis	
1200	1300	Lunch		

MOVING FROM LICENSING TO INTRODUCTION (2)

Chairperson: H Margolis

1300	1400	The changing regulatory environment: the rotavirus vaccine case Asian regulatory perspective and trends	K Low	TAB 16
1400	1430	Regulatory pathways and procedure for acceptability of vaccines for purchase by UN agencies	L Chocarro	TAB 18
1430	1445	Coffee break		
1445	1530	AEFIs and risk communication	F Andre	TAB 19
1530	1700	Round table discussion: The science, practice, public opinion - a pragmatic approach?	Chaired by F Andre Participants: L Chocarro, H Margolis, L Jodar	TAB 20

DAY 4: Thursday, May 10, 2006

PRODUCT DEVELOPMENT PARTNERSHIPS

Chairperson: U Griffiths

900	1100	PPPs: 3 models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: Group A meningococcal vaccines (40 mins) Malaria vaccines (40 mins) HPV vaccines (40 mins)	L Jodar K Amfo V Tsu	TAB 24 TAB 25 TAB 26
1100	1115	Coffee break		
1115	1135	Technology transfer	R Carbis	TAB 27
1135	1220	Round table discussion:	Chaired by: R Mahoney R Carbis, K Amfo, L Jodar, H Margolis, V Tsu	
1220	1330	Lunch		

PRODUCT DEVELOPMENT PARTNERSHIPS (2)

Chairperson: D Kohl

1330	1500	The Pediatric Dengue Vaccine Initiative and Dengue Vaccines: a case study overview lectures - epidemiology, vaccines, diagnostics and vaccine access	H Margolis, B Letson, D Edgil, M Beatty, R Mahoney	TAB 28
1500	1630	Break-out Groups: identification of barriers to evaluation and introduction of dengue vaccines and how to overcome Coffee break (during the breakout session)	H Margolis, J Kuritsky, D Edgil, B Letson, M Beatty, R Mahoney	TAB 29
1630	1730	Group discussion: conclusions from breakout groups and discussion	J Kuritsky	

DAY 5: Friday, May 11, 2006

MOVING FROM LICENSURE TO USE (3)

Chairperson: F Andre

830 915 Health economics: principles and methods U Griffiths TAB 30

915 1015 Development of investment cases for accelerated introduction of typhoid vaccines in selected countries in Asia
Case study: Vietnam L Jodar TAB 31

1015 1030 Coffee break

1100 1230 Introduction of new vaccines in the Asia-Pacific region:
Challenges and opportunities M Rani TAB 32
Hib vaccine introduction in the region M Rani TAB 33
Pneumococcal Vaccine introduction M Knoll TAB 34
Rotavirus vaccine introduction T Nelson TAB 35
Discussion on participant's practical experiences

1230 1330 Lunch

Programmatic Considerations:

1330 1400 Financing mechanisms: the GAVI model U Griffiths TAB 36
1400 1500 Round table discussion Chaired by L Jodar
F Andre, M Rani, U Griffiths

1500 1515 Coffee break

Chairperson: M Rani

1515 1630 Sharing experience: injection safety assessment and adverse event monitoring
Discussion on participants' practical experiences A Amarasinghe TAB 37

1630 1645 Coffee break

1645 1800 Sharing experience: vaccine introduction in GAVI Programs
- cold chain, logistics D Kohl TAB 38
Discussion on participants' practical experiences

DAY 6: Saturday, May 12, 2006

SPECIAL LECTURES

Chairperson: L Jodar

9000 1030 Keynote closing speech - the future of vaccines and vaccination with special emphasis on avian flu and other pandemics F Andre TAB 39

1030 1100 Coffee break

1100 1200 Closing ceremony J Clemens/L Jodar

1200 1400 Lunch